Olanzapine-induced obesity and diabetes in Indian patients: A prospective trial comparing olanzapine with typical antipsychotics

Journal of the Indian Medical Association

Volumn 103, Issue 12, 2005, Pages 660-664

  Guha, Prathama ^a   Roy, Krishna ^b   Sanyal, Debashis ^c   Dasgupta, Tirthankar ^d   Bhattacharya, Kaberi ^d  

^a CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

^b MEDICAL COLLEGE AND HOSPITAL   (India)

^c NORTH BENGAL MEDICAL COLLEGE   (India)

^d North Bengal Medical College and Hospital ^*

Author keywords

Hyperglycaemia; Obesity; Olanzapine induced diabetes

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INDIA; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 33744736285     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Thonnard-Neumann E - Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124: 978-82.
2. Fertig MK, Brooks VG, Shelton PS, English CW - Hyperglycaemia associated with olanzapine. J Clin Psychiatry 1998; 44: 778-83.
3. Leslie DL, Rosenheck RA - Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004; 161: 1709-11.
4. Semyak MJ, Alarcon RD, Losonczy MF, Rosenheck R - Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-6.
5. Morteiisen PB, Juel K - Mortality and causes of in first admitted schizophrenic patients. Br J Psychiatry 1993; 163: 183-9.
6. Lindenmayer JP, Czober P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al - Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsycliotics. Am J Psychiatry 2003; 160: 290-6.
7. Gaulin BD, Markowitz JS, Caley CF - Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270-2.
8. Nguyen M, Murphy T - Olanzapine hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry 2001; 40: 133-6.
9. Koller EA, Doraiswamy PM - Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22: 841-52.
10. Haupt DW, Newcomer JW - Hyperglycemia and antipsychotic medication. J Clin Psychiatry 2001; 62: 15-26.
11. Kay SR, Opler LA, Lindenmayer JP - Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.
12. Dwyer J - Nutritional requirements and dietary assessment. In: Braunwald E, Hauser SL, Fauci AS, Longo DL, Kasper DL, Jameson JL, editors. Harrison's Priniciples of Internal Medicine. 15th ed. New York: McGraw-Hill, 2003: 451-4.
13. Powers AC - Diabetes mellitus. In: Braunwald E, Hauser SL, Fauci AS, Longo DL, Kasper DL, Jameson JL, editors. Harrison's Priniciples of Medicine. 15th ed. New York: McGraw-Hill, 2003: 2109-37.
14. Amdisen A - Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964; 11: 182-9.
15. Pijl H, Meinders AE - Bodyweight change as an adverse effect of drug treatment: mechanism and management. Drag Saf 1996; 14: 329-42.
16. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC - Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-83.
17. Lean MEJ, Pajonk FG - Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003; 26: 1597-605.